Cargando…
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
Chimeric antigen receptor T-cell (CAR-T) therapy is an exciting development in the field of cancer immunology and has received a lot of interest in recent years. Many time-to-event (TTE) endpoints related to relapse, disease progression, and remission are analyzed in CAR-T studies to assess treatmen...
Autores principales: | Li, Yimei, Hwang, Wei-Ting, Maude, Shannon L., Teachey, David T., Frey, Noelle V., Myers, Regina M., Barz Leahy, Allison, Liu, Hongyan, Porter, David L., Grupp, Stephan A., Shaw, Pamela A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481718/ https://www.ncbi.nlm.nih.gov/pubmed/35838646 http://dx.doi.org/10.1158/1078-0432.CCR-22-0560 |
Ejemplares similares
-
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018) -
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018) -
Sars-Cov-2 Infections in CAR T Cell Recipients
por: McNerney, Kevin O., et al.
Publicado: (2021) -
Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020) -
The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)